Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRIO NASDAQ:LUCD NASDAQ:PDEX NASDAQ:RXST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$6.47+2.1%$7.53$5.85▼$17.74$47.26M1.1112,684 shs481 shsLUCDLucid Diagnostics$1.04+0.5%$1.07$0.90▼$1.63$210.17M1.081.16 million shs82,461 shsPDEXPro-Dex$64.71+2.1%$59.39$23.47▼$68.99$206.43M-0.0233,685 shs2,573 shsRXSTRxSight$5.35+2.5%$5.94$4.48▼$13.96$221.60M1.14877,037 shs38,227 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth-5.52%-17.04%-23.79%-22.21%-56.29%LUCDLucid Diagnostics0.00%+0.98%-3.74%-13.45%-13.45%PDEXPro-Dex-1.57%+1.72%-0.20%+30.41%+51.58%RXSTRxSight+5.24%+11.54%-14.29%-20.79%-61.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$6.47+2.1%$7.53$5.85▼$17.74$47.26M1.1112,684 shs481 shsLUCDLucid Diagnostics$1.04+0.5%$1.07$0.90▼$1.63$210.17M1.081.16 million shs82,461 shsPDEXPro-Dex$64.71+2.1%$59.39$23.47▼$68.99$206.43M-0.0233,685 shs2,573 shsRXSTRxSight$5.35+2.5%$5.94$4.48▼$13.96$221.60M1.14877,037 shs38,227 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth-5.52%-17.04%-23.79%-22.21%-56.29%LUCDLucid Diagnostics0.00%+0.98%-3.74%-13.45%-13.45%PDEXPro-Dex-1.57%+1.72%-0.20%+30.41%+51.58%RXSTRxSight+5.24%+11.54%-14.29%-20.79%-61.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRIODarioHealth 2.00Hold$10.5062.21% UpsideLUCDLucid Diagnostics 2.60Moderate Buy$4.19304.59% UpsidePDEXPro-Dex 2.33Hold$70.008.17% UpsideRXSTRxSight 1.93Reduce$9.4476.56% UpsideCurrent Analyst Ratings BreakdownLatest DRIO, LUCD, RXST, and PDEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/8/2026LUCDLucid Diagnostics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $9.255/22/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026PDEXPro-Dex Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LUCDLucid Diagnostics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/15/2026LUCDLucid Diagnostics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.505/14/2026DRIODarioHealth Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00 ➝ $10.005/13/2026DRIODarioHealth TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$11.005/12/2026PDEXPro-Dex Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.005/7/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026RXSTRxSight Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$11.00 ➝ $9.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRIODarioHealth$22.36M2.12N/AN/A$10.05 per share0.64LUCDLucid Diagnostics$5.13M40.94N/AN/A($0.31) per share-3.34PDEXPro-Dex$66.59M3.10$3.15 per share20.54$11.23 per share5.76RXSTRxSight$127.48M1.74N/AN/A$6.70 per share0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRIODarioHealth-$41.71M-$8.88N/AN/AN/A-192.23%-60.52%-37.08%8/11/2026 (Estimated)LUCDLucid Diagnostics-$58.01M-$0.47N/AN/AN/A-876.72%N/A-116.26%8/12/2026 (Estimated)PDEXPro-Dex$8.98M$3.6217.8823.28N/A16.08%22.78%14.30%7/8/2026 (Estimated)RXSTRxSight-$38.94M-$1.13N/AN/AN/A-36.58%-17.01%-15.12%8/6/2026 (Estimated)Latest DRIO, LUCD, RXST, and PDEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LUCDLucid Diagnostics-$0.05-$0.07-$0.02-$0.17$1.38 million$1.26 million4/30/2026Q3 2026PDEXPro-Dex$0.62$1.20+$0.58$1.20$17.90 million$19.95 million3/25/2026Q4 2025LUCDLucid Diagnostics-$0.07-$0.10-$0.03-$0.12$1.39 million$1.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRIODarioHealthN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRIODarioHealth0.503.072.62LUCDLucid DiagnosticsN/A1.071.05PDEXPro-Dex0.323.672.14RXSTRxSightN/A10.208.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRIODarioHealth33.39%LUCDLucid Diagnostics74.01%PDEXPro-Dex15.28%RXSTRxSight78.78%Insider OwnershipCompanyInsider OwnershipDRIODarioHealth3.50%LUCDLucid Diagnostics6.90%PDEXPro-Dex45.90%RXSTRxSight10.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRIODarioHealth2007.31 million7.06 millionNo DataLUCDLucid Diagnostics70203.07 million189.06 millionNo DataPDEXPro-Dex1403.19 million1.73 millionNot OptionableRXSTRxSight22041.40 million37.24 millionOptionableDRIO, LUCD, RXST, and PDEX HeadlinesRecent News About These CompaniesRxSight (NASDAQ:RXST) Trading 4.9% Higher - Still a Buy?June 23 at 2:21 AM | americanbankingnews.comRxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology ForumMay 19, 2026 | globenewswire.comRxSight, Inc. (RXST) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comRxSight (RXST) Q1 2026 Earnings TranscriptMay 12, 2026 | finance.yahoo.comRxSight, Inc. (RXST) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comRxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2026 | zacks.comRxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales OutlookMay 6, 2026 | globenewswire.comHow The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target ResetsMay 4, 2026 | finance.yahoo.comRxSight, Inc. to Present at the Bank of America Healthcare ConferenceApril 29, 2026 | globenewswire.comRxSight, Inc. to Report First Quarter 2026 Financial Results on May 6April 22, 2026 | globenewswire.comHow The RxSight (RXST) Story Is Shifting With New Guidance And Street Price TargetsApril 19, 2026 | finance.yahoo.comRxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026April 8, 2026 | globenewswire.comHow The Story Is Shifting For RxSight (RXST) On Guidance Leadership And ValuationApril 5, 2026 | finance.yahoo.comRxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 2, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX)March 12, 2026 | theglobeandmail.comHow The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO ChangeMarch 7, 2026 | finance.yahoo.comRXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 GuidanceFebruary 26, 2026 | markets.businessinsider.comRxSight (RXST) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | finance.yahoo.comRxSight, Inc. (RXST) Q4 2025 Earnings Call TranscriptFebruary 25, 2026 | seekingalpha.comRxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue EstimatesFebruary 25, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRIO, LUCD, RXST, and PDEX Company DescriptionsDarioHealth NASDAQ:DRIO$6.47 +0.13 (+2.10%) As of 10:00 AM Eastern This is a fair market value price provided by Massive. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Lucid Diagnostics NASDAQ:LUCD$1.03 +0.01 (+0.49%) As of 10:02 AM Eastern This is a fair market value price provided by Massive. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Pro-Dex NASDAQ:PDEX$64.71 +1.32 (+2.08%) As of 10:01 AM Eastern This is a fair market value price provided by Massive. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.RxSight NASDAQ:RXST$5.35 +0.13 (+2.47%) As of 10:02 AM Eastern This is a fair market value price provided by Massive. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
